Xintian Li

Xintian Li has extensive experience working as a scientist in various research institutions. From 2021 to present, they have been employed as a Scientist at Armata Pharmaceuticals, Inc., focusing on phage therapy projects aimed at combating antibiotic-resistant pathogens. Prior to this, from 2016 to 2021, Xintian Li worked as a Scientist at Leidos Biomedical Research, Inc., where they developed innovative strategies for creating phage vaccines using DNA recombineering and CRISPR technologies. From 2014 to 2016, Xintian Li held the position of Project Scientist at the Department of Physics, University of California San Diego (UCSD), where they conducted quantitative analysis of microbial growth and cell cycle mechanisms. They also worked as a Research Fellow and Postdoctoral Fellow at the National Cancer Institute-Frederick from 2008 to 2014, focusing on studying lambda phage Red-mediated recombination. Furthermore, Xintian Li served as a Postdoctoral Associate at the Department of Pharmacology, Weill Medical College of Cornell University, from 2006 to 2008, studying the molecular mechanisms of the environmental toxin TCDD. Finally, from 2003 to 2006, Xintian Li worked as a Postdoctoral Associate at the Department of Biochemistry, Weill Medical College of Cornell University, where they focused on studying Diabetes Insipidus and neurophysin dimerization and folding.

Xintian Li's education history includes achieving a bachelor's degree in Biology from Hubei University from the years 1986 to 1990. Following that, they pursued a master's degree in Biochemistry and Molecular Biology from Wuhan University from 1994 to 1997. Xintian Li furthered their education by completing a Doctor of Philosophy (PhD) in Biochemistry and Molecular Biology from Jointly Hong Kong University and Peking Union Medical College between 1999 and 2002.